Continuing a collaborative research agreement signed in 2016, Neon Therapeutics licensed technology from the [Netherlands Cancer Institute] (NKI) that will enable it to advance its personalized neoantigen T-cell therapy candidate NEO-PTC-01 into clinical development.
The agreement announced Oct. 4 grants the Cambridge, Mass.-based biotech exclusive intellectual property rights for an ex vivo induction platform...








